US Patent

US8946276 — High dosage mucoadhesive metronidazole aqueous-based gel formulations and their use to treat bacterial vaginosis

Method of Use · Assigned to Actavis Laboratories UT Inc · Expires 2032-06-28 · 6y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects high-dosage mucoadhesive metronidazole gel formulations for treating bacterial vaginosis through intravaginal application.

USPTO Abstract

The present disclosure provides mucoadhesive aqueous-based gel formulations of metronidazole useful for a variety of purposes, including intravaginal application as a therapeutic approach towards the treatment of individuals suffering from and/or diagnosed with bacterial vaginosis.

Drugs covered by this patent

Metro I.V. In Plastic Container (METRONIDAZOLE) · Baxter

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1664`	—	Metro I.V. In Plastic Container

Patent Metadata

Patent number: US8946276
Jurisdiction: US
Classification: Method of Use
Expires: 2032-06-28
Drug substance claim: No
Drug product claim: No
Assignee: Actavis Laboratories UT Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.